| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2887951 | Annals of Vascular Surgery | 2010 | 8 Pages |
Abstract
TER was necessary in more than one-third of limbs to maintain 2-year SSCS in 49% of patients. EVI was twice as expensive as estimated 2-year costs for supervised exercise and pharmacotherapy, and 10 times more costlier than a 3-month trial. Mandating a trial of conservative therapy before EVI merits consideration.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Monica S. O'Brien-Irr, Linda M. Harris, Hasan H. Dosluoglu, Maciej L. Dryjski,